Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibin beta E chain (INHBE) is a member of the transforming growth factor-beta (TGF-beta) superfamily of proteins that is predominantly expressed in the liver and encodes the beta-E subunit, which homodimerizes to form the biologically active hepatokine Activin E. Activin E acts as a ligand that binds to ALK7 (ACVR1C) receptors on adipocytes, activating SMAD2/3 signaling to suppress lipolysis and promote lipid storage and fat accumulation. Human genetic studies have shown that individuals with loss-of-function mutations in the INHBE gene exhibit healthier fat distribution, improved metabolic profiles, and a lower risk of type 2 diabetes and coronary heart disease. Consequently, INHBE has emerged as a highly promising therapeutic target for the treatment of obesity, overweight, and metabolic dysfunction-associated steatohepatitis (MASH). Therapeutic strategies under development primarily utilize liver-directed small interfering RNAs (siRNAs), such as ARO-INHBE, IBI3046, RBD3133, and CMS-D008, to selectively silence hepatic INHBE expression. By reducing circulating Activin E levels, these therapies relieve the inhibition of lipolysis, promoting fat-selective weight loss while preserving lean muscle mass, either as monotherapies or in combination with GLP-1 receptor agonists.
RNA interference (RNAi) mediated gene silencing of hepatic INHBE expression to reduce circulating Activin E levels, thereby blocking Activin E-ALK7 signaling, increasing lipolysis, and reducing fat accumulation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibin beta E chain (INHBE).